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The serpin family comprises a structurally similar, yet functionally diverse, set of proteins. Named originally for their
function as serine proteinase inhibitors, many of its members are not inhibitors but rather chaperones, involved in
storage, transport, and other roles. Serpins are found in genomes of all kingdoms, with 36 human protein-coding
genes and five pseudogenes. The mouse has 60 Serpin functional genes, many of which are orthologous to human SER-
PIN genes and some of which have expanded into multiple paralogous genes. Serpins are found in
tissues throughout the body; whereas most are extracellular, there is a class of intracellular serpins. Serpins appear to
have roles in inflammation, immune function, tumorigenesis, blood clotting, dementia, and cancer metastasis. Further
characterization of these proteins will likely reveal potential biomarkers and therapeutic targets for disease.
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Metastatic cancerIntroduction
Serpins represent the largest and most functionally diverse
family of protease inhibitors. The name serpin originates
from the first described function of this family, viz., serine
proteinase inhibitors. In their native state, serpins exist as
monomeric proteins. Most serpin family members inhibit
serine proteinases of the chymotrypsin family [1],
thereby inhibiting proteolytic cascades. However, some
serpins exhibit functions unrelated to inhibition of cata-
lytic activity, such as hormone transport and other
mechanisms.
Approximately 1,500 serpin sequences have been identi-
fied; they are found in the genomes of all five kingdoms [2].
There are 36 identified human putatively functional protein-
coding genes [3]. The serpin superfamily is divided into
groups called clades according to their sequence simi-
larity. Clades are classified as A–P, with clades A–I repre-
senting human serpins [4].* Correspondence: dan.nebert@uc.edu; vasilis.vasiliou@ucdenver.edu
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reproduction in any medium, provided the orSerpins have well-conserved secondary structures with an
exposed reactive center loop (RCL) (Figure 1), which inter-
acts with the protease active site to inhibit protease activity
[5]. The ability for serpins to undergo conformational change
is crucial for their function, in which serpins act via a suicide
substrate inhibitory mechanism [2,4]. Although most serpins
selectively inhibit serine proteases, some inhibit cysteine pro-
teases, such as caspases and cathespins; others perform hor-
mone transport and blood pressure regulation [4]. Serpins play
important physiological roles in hormone transport, cortico-
steroid binding, coagulation, and blood pressure regulation.
Serpin nomenclature
Initially named for tissue location or function (Table 1),
a nomenclature committee convened in 1999 with the
goal of standardizing serpin gene nomenclature [4].
‘SERPIN’ was designated as the gene symbol for humans
and other species because it is well known and used in
the literature and as a keyword [4]. Serpins were not
named for activity or function due to the diversity of
member structure and tissue distribution. In 2005, pro-
teinase in human gene names was replaced with the
term peptidase; however, ‘serpin’ remains the stem be-
cause the name was designated prior to this change. The
current classification of serpins involves division into
clades that are based on phylogenetic relationships. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
RCL 
-sheet “A” 
Figure 1 Native SERPINA1. Native SERPINA1 with labeled structural elements: β sheet a and reactive center loop (RCL); α helices in red, β sheets
in turquoise, turns in green. (Adapted from PDB 1HP7).
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pins are represented in the first nine clades (i.e., A–I),
with a variety of members being in each clade. Clades
are phylogenetically unique and it is important to
recognize that no relationships between the clade letters
are implied by their order [4]. Some serpins are classified
as orphans because they do not group with any other
clade. It is likely that they will form clades as new ser-
pins are identified. An example to help illustrate the no-
menclature would be α-1-antitrypsin. This was assigned
to the first clade, giving it the symbol SERPINA1 with
the ‘A’ referencing the clade and the ‘1’ referencing the
gene number within the clade [4].
Structure function
Serpins have a metastable structure that is required for
their function. It consists of a highly conserved secon-
dary structure with three β-sheets (A, B, and C), nine
α-helices and a RCL (Figure 1), which serve as bait for
target proteases [4,6]. Well-conserved throughout the
serpin family, the tertiary structure of scaffold allows for
a conformational change critical to protease inhibitor ac-
tivity [4]. In their native state, serpins exist as monomeric
proteins. A serpin molecule consists of a single 330- to
500-amino acid polypeptide chain that has conserved
secondary helices and sheets. To inhibit proteolytic acti-
vity, the serpin acts as a suicide substrate for the protease
[4]. This is accomplished by the RCL of the serpin inter-
acting with the protease's active site [6].
Serpins can exist in several forms, viz., active, latent,
cleaved, delta, and polymeric. Each form is defined by the
RCL, which is the moiety required for inhibitory activity.
The active form (or the native state) has an exposed RCLthat allows it to interact with the protease. The RCL
forms an exposed extension located above the mo-
lecule. Following proteolysis, the amino acid terminus
of the RCL inserts into the A β sheet forming a fourth
strand. This process is called the ‘stressed (S) to re-
laxed (R) transition’ [3] used to inhibit proteases,
resulting in the cleaved form. The cleaved form is ne-
cessary for inhibition of proteases resulting in an irre-
versible covalent complex with the target protease thus
inactivating both the serpin and the target. Some serpins
bind cofactors and/or glycosaminoglycans to maximize
protease inhibition, which can vastly increase inhibitory
potential [7].
The native form of serpins has low thermal stability indi-
cating that it is not the most stable conformation; rather,
native serpins are metastable. However, not all serpins
undergo this transition. Serpins can transition to the latent
form from the active form and back to the active form
from the latent form. The latent form does not possess in-
hibitory activity but it can convert to the active form
through denaturation and refolding [4]. Consequently, it
can be considered a control mechanism in regulating
homeostasis for certain serpins [3]. Alternatively, the
latent state caused by a mutation can be pathological [3].
The delta form is an intermediate conformation be-
tween latent and native state where the RCL inserts into
the A β sheet and one of the helices unwinds and com-
pletes hydrogen bonding of the β sheet [3]. Little is
known about the function of this conformation; how-
ever, it is likely that this favors polymeric or latent
conformation transition rather than native. The poly-
meric form has a loop sheet mechanism whereby the
RCL that would be inserted into the same serpin is
Table 1 SERPIN aliases and function
Clade name Clade Serpin gene
name
Known aliases Biological function References
Alpha 1 proteinase
inhibitor antitrypsin
A SERPINA1 Alpha 1PI Inflammation, complement activation, apoptosis 17
SERPINA2
SERPINA3 Alpha1 ACT Apoptosis, Alzheimer’s disease, prohormone
conversion, inflammation and complement
activation
3,16
SERPINA4 PI4, KST, KAL Kidney function, inflammation, and complement
activation
18
SERPINA5 PCI Coagulation, inflammation, complement
activation, sperm development
SERPINA6 CBG Hormone transport 16
SERPINA7 TBG Hormone transport
AGT SERPINA8 Blood pressure regulation, renal development 19
SERPINA9 Centurin B cell development 3
SERPINA10 PZI Inhibition of activated factors Z and XI 3
SERPINA11
SERPINA12 Vaspin Inhibits kallikrein; unknown role in insulin
sensitivity
20,21
SERPINA13P
SERPINB1 PI2, LEI, MNEI, EI Inflammation, complement activation 3
SERPINB2 PAI2, placental PAI, monocyte
ARG serpin, PLANH2
Fibrinolysis, elastase inhibitor 3
ov Serpins B SERPINB3 SCCA1, SCC Inhibition of cathepsins, tumor promotion 32
SERPINB4 SCCA2, PI11 Inhibition of cathepsins and chymase 33
SERPINB5 Maspin, PI5 Tumor cell invasion, angiogenesis 3
SERPINB6 DFNB91, PI6, CAP Cathepsin inhibitor 34
SERPINB7 Megsin Renal development, mesangial cell proliferation 35
SERPINB8 PI8, CAP2 Uncharacterized 3
SERPINB8P1
SERPINB9 PI9, CAP3
SERPINB10 PI10, BOMAPIN Hematapoetic and myeloid development 35
SERPINB11 EPIPIN Uncharacterized 36
SERPINB12 YUKOPIN Trypsin inhibition 37
SERPINB13 PI13, headpin, HUR7, hurpin
Antithrombin C SERPINC1 AT3, ATIII, antithrombin3 Coagulation, angiogenesis 38
Heparin cofactor D SERPIND1 HCFII, HCF2, heparin cofactor II,
HLS2
Coagulation 40
Nexin/plasminogen
activator inhibitor 1
E SERPINE1 PAI, PLANH1 Angiogenesis, fibrinolysis 3
SERPINE2 PI7, GDN, ‘glial-derived nexin 1,’
nexin, PN1, PNI
Neurotrophic factor 41
SERPINE3
Alpha 2 antiplasmin
pigment epithelium
derived factor
F SERPINF1 PEDF Neurotrophic factor, angiogenesis 16
SERPINF2 Alpha 2AP, PLI, A2AP, AAP,
‘alpha-2-antiplasmin,’ ALPHA‐2‐PI,
‘alpha‐2‐plasmin inhibitor,’ API
Fibrinolysis 3
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Table 1 SERPIN aliases and function (Continued)
C1 inhibitor G SERPING1 C1NH,C1–INH, C1IN, HAE1,
HAE2, ‘plasma protease C1
inhibitor’
Microbial infection 42
Heat shock protein H SERPINH1 CBP1, CBP2, collagen, HSP47 Chaperone 43
Neuroserpin I SERPINI1 Neuroserpin, PI12 Neurotrophic factor 46
SERPINI2 Pancpin, PI14, TSA2004, MEPI Tumor cell invasion 47
SERPINS are divided into clades and gene name with known aliases and biological function are provided. Alternative name information was determined using
HGNC (http://www.genenames.org) and/or MGI (www.informatics.jax.org).
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forming a long chain of these molecules [3]. However,
this mechanism of polymerization has recently been
challenged in favor of that of a domain-swapping
model [8]. Serpins are unique in that their native state
(active form) is not the most kinetically stable; rather,
it is ‘metastable’. By incorporating the RCL into their
A β sheet, either by cleavage for inhibition of target
protease or spontaneous latency, they become more
stable [9]. For an excellent minireview on kinetics of
serpins, see Silverman et al. [4].
Evolution
Whereas serpins have highly conserved secondary and
tertiary structures upon which they are grouped, they
often share little amino acid sequence similarity. They
do, however, share a highly conserved core, especially in
the shutter domain including Ser56 and Ser53 [10],
which is thought to be critical in determining tertiary
structure and conformational flexibility.
Due to the numerous, yet distinct, processes regulated
by serpins and their widespread functions, serpins offer
a unique perspective for protein evolution. Members of
the serpin family tend to group phylogenetically by spe-
cies rather than by function. Therefore, evolution of the
serpin family was likely driven by speciation to fill their
physiological roles rather than by coevolution with the
serine proteases (which group by function) [10]. Nume-
rous serpin genes are also found in clusters on the same
chromosomes, reflecting earlier gene-duplication events
and potentially indicating a common precursor [11,12].
Interestingly, these genes are functionally divergent, des-
pite their chromosomal proximity [7]. In addition, ser-
pins have distinct patterns of introns and exons. These
patterns may contain information regarding phylogenetic
signals and be evolutionarily related based on relative
intron positioning [13,14].
The distribution of serpins in eukaryotes suggests that
they arose early in eukaryotic evolution [1]. Extensive
gene clustering indicates that numerous serpins in close
proximity on the same chromosome may have arisen as
a result of duplications from a common precursor [12];
however, the evolution of these proximal genes gave way
to vastly divergent functions.Intracellular serpins of clade B are ancestral to most
extracellular serpins [15,16] and each inhibitory serpin
contains a highly conserved hinge region [16] within the
RCL. Clade F serpins specifically share ancestry with a sea
lamprey serpin. Clade P is specific to plant serpins which
form a discrete clade. At the time of divergence be-
tween Viridiplantae and fungi/Metazoa groups, there
was likely only one serpin gene [16]; however, the an-
cestral homolog from prokaryote or fungi has not yet
been identified [16].
There are eight human serpin pseudogenes listed in
Table 2. SERPINA15P has been named in succession for
the A clade with the parent gene SERPINA6 according
to Ensembl and SERPINE2 is the parent gene for SERPI-
NE4P, again named in sequence of the E clade. There
are ten mouse pseudogenes listed (Table 3) which re-
main uncharacterized.Methods
Protein sequences for human serpins were accessed from
Uniprot through the HUGO Gene Nomenclature Commit-
tee website (http://www.genenames.org). Sequences were
retrieved from the National Center for Biotechnology
Information (NCBI) gene database (http://www.ncbi.nlm.
nih.gov/gene) referenced through the HUGO Gene No-
menclature Committee website (http://www.genenames.
org) for humans and MGI website (http://www.informatics.
jax.org) for mouse. All sequences were aligned using the
most accurate settings of T-Coffee (http://tcoffee.crg.cat/)
and phylogenetic trees were constructed using neighbor-
joining methods with 1000 replicate bootstrap in PHYLIP
3.69 (http://evolution.genetics.washington.edu/phylip.html)
(Figure 2). Expression data were determined using Gene-
cards (http://www.genecards.org) and alternative name
information was determined using HGNC (http://www.
genenames.org) or MGI (www.informatics.jax.org).Human and mouse serpin isoforms
Clade A
Clade A serpins are classified as antitrypsin-like, extra-
cellular proteins. They are the largest of the eight clades
of extracellular serpins. The SERPINA clade has eleven
human genes (1, 3–12) and two pseudogenes.
Figure 2 SERPIN phylogenetic tree. Phylogenetic tree of human and mouse serpin proteins. Protein sequences were aligned using TCOFFEE
and analysed using neighbour-joining methods with 10,000 bootstrap replicates in the Phylip package.
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http://www.humgenomics.com/content/7/1/22SERPINA1 is an inhibitory serpin formerly known as
antitrypsin. It plays a role in the inhibition of neutrophil
elastase [3,17].
SERPINA2 was initially classified as a pseudogene; how-
ever, recent evidence indicates that it produces an active
transcript that encodes a protein located in the endoplas-
mic reticulum [18]. A study that sequenced SERPINA2
genes across multiple ethnic groups indicated that in
addition to active SERPINA2 protein, there is a haplotype
characterized by a partial deletion which has patterns
suggestive of positive selection for loss-of-function of
SERPINA2 protein. They suggest that the partial pseu-
dogenization in humans may indicate an ongoing process
of pseudogenization [19].
SERPINA3 is an inhibitory protein formerly known as
antichymotrypsin. It inhibits chymotrypsin and cathepsin G
[3,16]. This serpin is normally found in blood, liver, kidney,
and lung.
SERPINA4 is an inhibitory protein formerly known
as kallistatin (PI4), which inhibits kallikrein [20]. It is
expressed in blood, liver, kidney, and heart.
SERPINA5, formerly a protein C inhibitor, inhibits
active protein C. It is present in blood, kidney and liver.
SERPINA6 was formerly known as corticosteroid-
binding globulin. It is a non-inhibitory protein that binds
hormones, i.e., cortisol [16].
SERPINA7, formerly thyroxine-binding globulin, is in-
volved in non-inhibitory thyroid hormone transport. It is
expressed in blood, kidney, and heart.
SERPINA8 is now referred to as angiotensinogen
(AGT), which is a hormone precursor. It has a distinct
serpin domain (phylogenetically unrelated to other clade
A members in the current analysis) and a distinct,
smaller, agt domain. This particular serpin domain ap-
pears to be more closely associated with SERPINF and
SERPING [21].
SERPINA9 appears to have a role in naïve B cell main-
tenance. Formerly called centerin, it is expressed in the
plasma and liver.
SERPINA10 is an inhibitory protein responsible for inhi-
bition of activated coagulation factors Z and XI [3]. Formerly
known as protein Z-dependent proteinase inhibitor, it is
expressed in blood and liver.
SERPINA11 is likely a pseudogene and is uncharacterized.
SERPINA12, formerly vaspin, inhibits kallikrein [22]
and plays a role in insulin sensitivity [23]. It appears to
be expressed in plasma, platelets, liver and heart.
In the mouse (Table 3), Serpina1 has been expanded to
include six members, a–f. Serpina3 has been expanded to
include nine members, a–c and f–n. The other clade a
members are orthologous to human genes. Serpina8, now
known as Agt in the mouse, is vital for the development
and function of the renin-angiotensin system [24]. It is
orthologous to AGT in humans.Clade B
Clade B consists of intracellular serpins, including ov-
serpins, which are ancestral to the extracellular serpins
[16]. Members of this subfamily have shorter C and N
termini than typical A members and also lack the
secretory signal peptide sequence [4]. There are 13 hu-
man genes in clade B and one pseudogene. Serpins in
clade B are important in inflammation and immune
system function as well as mucous production [25]. SER-
PINB1, B6, B7, and B9 are involved in immune system
function with roles in neutrophil and megakaryocyte de-
velopment [26,27], as well as in the inhibition of the
cytotoxic granule protease granzyme B [28]. SERPINB3
and its close homolog B4 are inhibitors that have roles
in mucous production [29] and are expressed in epithe-
lial tissues, such as tongue, tonsils, uterus, cervix, and
vagina as well as in the upper respiratory tract and thy-
mus [30].
Despite elusive function, SERPINB3 appears to have a
role in apoptotic regulation and immunity, which impli-
cates B3 in tumor metastasis and autoimmunity [30].
SERPINB5 has been shown to inhibit metastasis
as a tumor suppressor in breast and prostate cancer
[30,31]. In addition, multiple serpins in the B clade have
been associated with oral squamous cell carcinoma,
specifically SERPINB12, SERPINB13, SERPINB4, SER-
PINB3, SERPINB11, SERPINB7, and SERPINB2 [32].
Less is known about SERPINB10–B13. However, recent
evidence points to a role for SERPINB13 in autoimmune
diabetes progression and in inflammation [33].
SERPINB1 is an inhibitor of neutrophil elastase. It was
formerly called monocyte neutrophil elastase inhibitor
and is expressed ubiquitously.
SERPINB2 inhibits PLAU (uPA). It was formerly called
plasminogen activator inhibitor 2 (PAI2) and is expressed
in blood, kidney, and liver.
SERPINB3 is a cross-class inhibitor of cathepsin L and V
[34]. Formerly referred to as squamous cell carcinoma anti-
gen 1, it is expressed in blood, immune cells, kidney, lung,
heart, and brain as well as numerous mucosal cells.
SERPINB4 was formerly known as squamous cell car-
cinoma antigen 2; it was discovered with SERPINB3
[25]. It is a cross-class inhibitor of cathepsin G and chy-
mase [35] and is found in plasma, platelets, kidney, and
heart, as well as saliva.
SERPINB5 is a non-inhibitory protein formerly called
maspin. It is likely expressed in blood, kidney, liver, lung,
as well as saliva.
SERPINB6, formerly called proteinase inhibitor 6 (PI6), is
an inhibitor of granule protease, cathepsin G [36]. It is
expressed ubiquitously.
SERPINB7 is involved in mesangial cell proliferation
[37]. Formerly called megsin, it is expressed in blood
and liver.
Table 2 Human SERPIN genes
Gene Entrez gene ID Chromosomal location # Exons # Amino acids # Alternative transcripts
SERPINA1 5265 14q32.1 5 418 10
SERPINA2P 390502 14q32.13 NA NA NA
SERPINA3 12 14q32.1 5 423 0
SERPINA4 5267 14q331–q32.1 5 427 0
SERPINA5 5104 14q32.1 6 406 0
SERPINA6 866 14q32.1 5 405 0
SERPINA7 6906 Xq22.2 5 415 0
SERPINA7P1 100422644 Xq22.3 NA NA NA
SERPINA9 327657 14q32.13 6 435 1
SERPINA10 51156 14q32.13 5 444 1
SERPINA11 256394 14q32.13 5 422 0
SERPINA12 145264 14q32.13 6 414 0
SERPINA13P 388007 14q32.13 5 NA NA
SERPINA15P * 8q23.3 NA NA NA
SERPINB1 1992 6p25 7 379 0
SERPINB2 5055 18q21.3 9 415 1
SERPINB3 6317 18q21.3 8 390 0
SERPINB4 6318 18q21.3 8 390 0
SERPINB5 5268 18q21.3 7 375 0
SERPINB6 5269 6p25 7 376 1
SERPINB7 8710 18q21.33 8 380 3
SERPINB8 5271 18q21.3 7 242 1
SERPINB8P1 11029 6p25 NA NA NA
SERPINB9 5272 6p25 7 376 0
SERPINB9P 221756 6p25.2 NA NA NA
SERPINB10 5273 18q21.3 7 397 0
SERPINB11 89778 18q21.33 8 392 0
SERPINB12 89777 18q21.33 7 405 0
SERPINB13 5275 18q21.3–q22 8 391 0
SERPINC1 462 1q23–q25.1 7 464 0
SERPIND1 3053 22q11.21 4 499 0
SERPINE1 5054 7q21.3–q22 9 402 1
SERPINE2 5070 2q33–q35 9 397 2
SERPINE3 647174 13q14.3 7 424 0
SERPINE4P * 15q12 NA NA NA
SERPINF1 5176 17p13.3 8 418 0
SERPINF2 5345 17p13 9 491 2
SERPING1 710 11q12–q13.1 8 500 1
SERPINH1 871 11q13.5 5 418 1
SERPINH1P1 158172 9p13.3 NA NA NA
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Table 2 Human SERPIN genes (Continued)
SERPINI1 5274 3q26.1 9 410 1
SERPINI2 5276 3q26 9 405 0
AGT 183 1q42.2 5 485 0
The human SERPIN family with indicated gene symbol, gene ID, chromosomal location, exon number, alternative transcript number, and number of amino acids.
Gene names not italicized are used here simply to underscore that these are pseudogenes for which little or no information is provided. Records are from the
National Center for Biotechnology Information (NCBI) gene database.
*Found in Ensembl.
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proteinase inhibitor 8 (PI8), it is expressed in blood and
heart.
SERPINB9 is an inhibitory protein. Formerly called
proteinase inhibitor 9 (PI9), it is expressed in blood,
liver, lung, and heart.
SERPINB10 is an inhibitory protein involved in
hematopoietic and myeloid development [37]. Formerly
called bomapin, it expressed in blood and possibly in the
brain.
SERPINB11 is a non-inhibitory serpin in human but
retains trypsin inhibitory activity in mice [38]. It appears
not to exhibit tissue-specific expression; however, it is
expressed in HEK cells.
SERPINB12 is a trypsin inhibitor formerly known as
yukopin [39]. It is expressed in blood, kidney, liver,
heart, and brain.
SERPINB13, formerly known as hurpin, is expressed in
blood, kidney, and saliva.
In clade b, mouse Serpinb1 has been expanded to in-
clude three members a–c; Serpinb3 as well as Serpinb6
have each expanded to include four members, a–d. In
mice, Serpinb4 is not listed; however, it appears that
SERPINB3 and SERPINB4 are equally related to Ser-
pinb3a, Serpinb3b, Serpinb3c, and Serpinb3d, despite the
initial theory that Serpinb3d is the mouse homolog of
human SERPINB3 and Serpinb3c is the mouse homolog
of SERPINB4. Serpinb9 has been expanded to seven
members and one pseudogene. Interestingly, Serpinb11
is an active proteinase inhibitor, whereas the human
ortholog is inactive.
Clade C
Serpin clade C consists of only one serpin member,
SERPINC1, more commonly known as antithrombin.
SERPINC1 inhibits coagulation factors IX and X [40]. It
is expressed in blood, kidney, liver, lung, heart, brain, as
well as saliva.
Serpinc1 gene encodes antithrombin and is ortholo-
gous to human SERPINC1.
Clade D
Clade D has one serpin member, SERPIND1, which is an
extracellular protein also known as heparin cofactor II[41]. It is an inhibitor of thrombin [42] and is expressed
in blood, kidney, liver, and heart.
Serpind1 encodes heparin cofactor II and is ortholo-
gous to SERPIND1.
Clade E
Clade E has three members, E1, E2, and E3, all of which
are extracellular.
SERPINE1, also known as plasminogen activator
inhibitor-1 (PAI1), inhibits thrombin. It is expressed in
blood, liver, and heart.
SERPINE2 is a glial-derived nexin that is important in
recovery of nerve structure and function [43]. It is
expressed in blood, liver, kidney, and brain.
Little is known about the function of SERPINE3.
The mouse genes in clade e (Serpine1–3) are ortholo-
gous to human SERPINE1–3.
Clade F
There are two members in SERPIN clade F.
SERPINF1 (or pigment epithelium-derived factor (PEDF))
regulates angiogenesis and is an example of a non-
inhibitory serpin. It is also thought to be a neurotrophic
factor [16], and appears to be expressed in blood, liver,
kidney, heart, and possibly lung.
SERPINF2, also known as α-2-antiplasmin, is an in-
hibitor of fibrinolysis. It is found in blood, kidney, liver,
and heart.
Mouse Serpinf1 and f2 genes are orthologous to the
human SERPINF1 and SERPINF2 genes, respectively.
Clade G
Clade G consists of one inhibitory serpin.
SERPING1 is a complement I esterase inhibitor [44]
formerly called C1 inhibitor. It is expressed in blood,
liver, kidney, lung, heart, and brain.
Mouse Serping1 encodes C1 inhibitor and is ortholo-
gous to SERPING1.
Clade H
Clade H consists of one member.
SERPINH1, also known as 47-kDa heat shock protein
(HSP47), does not act as a proteinase inhibitor, but
Table 3 Mouse Serpin genes
Mouse gene Entrez gene ID Chromosomal location # Exons # Amino acids # Alternative transcripts
Serpin1a 20700 12; 12 51.0 cM 7 413 2
Serpin1b 20701 12; 12 51.0 cM 5 413 1
Serpin1c 20702 12; 12 51.0 cM 5 413 0
Serpin1d 20703 12; 12 51.0 cM 5 413 0
Serpin1e 20704 12 E; 12 5 413 1
Serpin1f 68348 12 E; 12 6 411 2
Serpina2-ps* NA 12 NA NA NA
Serpina3d-ps 435318 12 E; 12 NA NA 0
Serpina3e-ps 628883 12 E; 12 NA NA 0
Serpina3a 74069 12 E; 12 5 422 1
Serpina3b 271047 12 E; 12 5 420 0
Serpina3c 16625 12 E; 12 5 417 0
Serpina3f 238393 12 E; 12 6 445 2
Serpina3g 20715 12 E; 12 6 440 3
Serpina3h-ps 546546 12 E; 12 5 NA 1
Serpina3i 628900 12 E; 12 4 408 1
Serpina3j 238393 12 E; 12 4 420 1
Serpina3k 20714 12 E; 12 15.5 cM 5 418 0
Serpina3l-ps 628916 12 E; 12 NA NA 0
Serpina3m 20717 12 E; 12 5 418 0
Serpina3n 20716 12; 12 F1 5 418 1
Serpina4-ps 321018 12 E; 12 NA NA NA
Serpina5 268591 12 F1 5 405 0
Serpina6 12401 12 51.0 cM 5 397 1
Serpina7 331535 X F1; X 6 426 2
Agt 11606 8 E2; 8 72.81 cM 5 482 0
Serpina9 71907 12 5 418 1
Serpina10 217847 12 5 448 1
Serpina11 380780 12 5 427 4
Serpina12 68054 12; 12 F1 5 413 0
Serpina13-ps* NA 12 NA NA NA
Serpinb1a 66222 13 A4; 13 12.0 cM 8 379 0
Serpinb1b 282663 13 A3.3, 13 12.6 cM 7 382 0
Serpinb1c 380839 13 A3.3, 12 12.2 cM 7 375 1
Serpinb1-ps 282665 13 A3.2, 13 13.76 cM NA NA 0
Serpinb2 18788 1 E2.1; 1 61.1 cM 11 415 3
Serpinb3a 20248 1 E2.1; 1 8 387 0
Serpinb3b 383548 1 E2.1; 1 8 387 0
Serpinb3c 381286 1; 1 E1-E2 8 386 0
Serpinb3d 394252 1E2.1; 1 7 387 0
Serpinb3-ps1 NA 1 NA NA NA
Serpinb3-ps2 NA 1 NA NA NA
Serpinb3-ps3 NA 1 NA NA NA
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Table 3 Mouse Serpin genes (Continued)
Serpinb5 20724 1 E2.1; 1 8 375 2
Serpinb6a 20719 1313 A3.3; 13 14.0 cM 11 378 16
Serpinb6b 20708 13 A3.3; 13 13.78 cM 7 377 2
Serpinb6c 97848 13 A3.3; 13 13.99 cM 7 378 0
Serpinb6d 238568 13 A3.3; 13 13.94 cM 6 375 0
Serpinb6e 435350 13 A3.3; 13 13.98 cM 8 429 1
Serpinb7 116872 1; 1 D 9 380 1
Serpinb8 20725 1; 1 D 7 374 3
Serpinb8-ps1* NA 1 NA NA NA
Serpinb9 20723 13 A3.3; 13 12.4 cM 8 374 0
Serpinb9b 20706 13 A3.3; 13 13.79 cM 7 377 0
Serpinb9c 20707 13 A3.3; 13 12.82 cM 8 387 2
Serpinb9d 20726 13 A3.3; 13 12.83 cM 7 377 0
Serpinb9e 20710 13 A3.3; 13 12.84 cM 7 377 0
Serpinb9f 20709 13 A3.3; 13 12.86 cM 7 377 0
Serpinb9g 93806 13 A3.3; 13 13.9 cM 7 377 0
Serpinb10 241197 1 E2. 1; 1 8 357 1
Serpinb11 66957 1 E2. 1; 1 8 388 0
Serpinb12 71869 1; 1 D 9 423 2
Serpinb13 241196 1 E2. 1; 1 9 389 1
Serpinc1 11905 1H2.1 84.6 cM 8 465 0
Serpind1 15160 16 A3; 16 9.5 cM 5 478 1
Serpine1 18787 5 G2; 5 9 402 1
Serpine2 20720 1 C4; 1 48.6 cM 9 397 1
Serpine3 319433 14 D1; 14 9 401 0
Serpinf1 20317 11 b5; 11 8 417 7
Serpinf2 18816 11 B5; 11 11 491 3
Serping1 12258 2 D; 2 8 504 0
Serpinh1 12406 7 E2; 7 6 417 1
Serpini1 20713 3 E3; 3 7 410 2
Serpini2 67931 3 E3; 3 8 405 0
The mouse serpin family with indicated gene symbol, gene ID, chromosomal location, exon number, alternative transcript number, and number of amino acids.
Gene names ending in "-ps" indicate a pseudogene for which little or no information is provided. Records are from the National Center for Biotechnology
Information (NCBI) gene database.
*=UCSC genome browser.
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blood, liver and heart.
Mouse Serpinh1 encodes HSP47 and is orthologous to
SERPINH1. Knockouts of Serpinh1 in mice are lethal
[46] and missense mutations are associated with osteo-
genesis imperfecta [47].
Clade I
Clade I consists of two extracellular proteins. Serpins in
clade I include the following.SERPINI1 is a neuroserpin inhibitor of PLAT (tPA),
PLAU (uPA), and plasmin [48]. It is expressed in liver
and possibly plasma.
SERPINI2, previously known as pancipin, has an un-
known protein target but may be involved in pancreatic
dysfunction [49]. It is found in platelets and plasma as
well as the heart.
The genes Serpini1 and Serpini2 encode mouse neuro-
serpin and pancipin, respectively. These are orthologous
to SERPINI1 and SERPINI2 in the human.
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Clades j–p represent viral, nematode, horseshoe crab,
blood fluke, and plant serpins [16] and will not be de-
scribed further in this update.Serpins associated with disease
Serpin polymorphisms have been associated with in
many disease states, including blood clotting disorders,
emphysema, cirrhosis, and dementia [15,16,50] as well
as tumorigenesis and metastasis.
Mutations in SERPINA1 result in a decrease in circu-
lating α-1-antitrypsin which is associated with emphy-
sema and hepatocellular carcinoma [51]. Serpins are
implicated in regulation of the cardiovascular system.
For example, SERPINA4 depletion is related to renal
and cardiovascular injury [52], SERPINA8 variations are
integral to the normal function of the renin-angiotensin
system and have been found to regulate blood pressure
[53], and a SERPINA10 polymorphism was found to in-
crease the risk of venous thromboembolism [54,55]. SER-
PINA3 deficiency is associated with emphysema [56].
Many SERPINBs are implicated in immune function
and dysfunction. In many of these cases, intracellular ser-
pins cause autoimmune antibody production, inflamma-
tion, neutropenia, and cancer metastasis [25]. SERPINC1
deficiency has been correlated with autoimmune disease,
especially in patients producing antinuclear antibodies,
such as those with systemic lupus erythematosus [30].
Interestingly, a SERPINA6 polymorphism has been asso-
ciated with chronic fatigue syndrome [57], which is
thought to be an immune disorder. SERPINA7 deficiency
is associated with hyperthyroidism, and high SERPINA12
levels have been associated with insulin resistance [23].
Mutations in SERPINH1, as well as in SERPINF1, are
associated with osteogenesis imperfecta [47,58].
Serpins appear to influence protein aggregation. In this
respect, SERPINI1 expression has been correlated with
dementia [4]. In addition, SERPINA5 accumulation has
been identified in plaques in multiple sclerosis [59] and
SERPINA3 polymerization may accelerate onset and
severity of Alzheimer's disease [30].
Many serpins have been implicated in cancer progres-
sion including SERPINBs (on the 18q21 locus) in oral
squamous cell carcinoma [25]. Breast and prostate
cancer metastases are also closely associated with SER-
PINB5 [60,61]. In addition, SERPINE1 appears to have a
role in tumor progression [62] and metastasis [63]. Fur-
ther, SERPINI2 may play a possible role in breast and
pancreatic cancer metastasis [49]. Adult gliomas have
significant associations with SERPINI1 [64], although its
role is unknown. In addition, SERPINI1 has also been
proposed as one of five biomarkers in hepatocellular car-
cinoma [65]. Another potential biomarker includesSERPINA9, which has been found to be strongly expressed
in B cell lymphomas [66].
Mouse models of human disease
There are numerous mouse models used to study the
role of SERPINs in disease. Some examples include
knockout of Serpinag3 used in studying T cells in im-
munology [67], hepatic specific knockout of Serpinc1,
which exhibits coagulopathy [68], and Agt knockout
to study blood pressure regulation and the renin-
angiotensin system where adipocyte-specific knockout
of agt caused decreased systolic blood pressure [69].
Serpinb1 knockout mice show neutropenia [70].
Gene variants in SERPINS
A large number of human variants of serpin genes
have been found. For example, NCBI's dbSNP database
(http://www.ncbi.nlm.nih.gov/snp) has 621 entries for
SNPs of SERPINA1 alone (accessed October 2013). In
addition, several groups have developed specific data-
bases for individual SERPIN genes. These include data-
bases for SERPINA1 [71], SERPINC3 [72], and
SERPING1 [73]. A number of pathologies in humans
have been attributed to SERPIN gene variants, and often
multiple deleterious mutations are known for each gene.
Although a full listing of disease-causing SERPIN muta-
tions is beyond the scope of this review, a sample of
their scope is provided here. Mutations in the SERPINA1
gene have been linked with early-onset pulmonary em-
physema, neonatal hepatitis, liver cirrhosis, and some-
times panniculitis and vasculitis [74,75]. SERPINA5
mutations have been linked with increased papillary thyroid
cancer risk [76], and mutations in SERPINA10 have been
linked to pregnancy complications [77]. Predisposition to
familial venous thromboembolic disease has been linked to
mutations in SERPINC1 [78,79]. Finally, SNP variants for
the SERPING1 gene have been shown to be associated with
hereditary angioedema [80].
Conclusions
Serpins are a large class of diverse proteins, which con-
tribute to numerous physiological and pathological con-
ditions. Identification of serpins in immunological
functions, pathology due to polymerization, and cancer me-
tastasis underscores their diverse functions and physio-
logical and pathological importance, and gene mutations
often lead to loss-of-function and pathology in affected in-
dividuals. However, there is still much to learn about the
functions and evolutionary development of serpins. Because
of numerous biological functions and pathological
states associated with serpins, further characterization
of these proteins and mechanistic information will
provide insight into potential biomarker identification
and therapeutic targets.
Heit et al. Human Genomics 2013, 7:22 Page 12 of 14
http://www.humgenomics.com/content/7/1/22Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CH carried out the sequence alignments and drafted the manuscript.
BJ participated in the sequence alignment and analysis. MM reviewed mouse
gene/protein data and the nomenclature for accuracy and completeness.
MW reviewed human gene/protein data and nomenclature for accuracy
and completeness. DT, GS and DWN reviewed and edited the manuscript.
VV designed the study and reviewed data and manuscript. All authors read
and approved the final manuscript.
Acknowledgements
This work was supported, in part, by the following NIH grants: R24
AA022057, NIEHS P30 ES06096, HG000330, U41HG003345 and also by a
Welcome Trust grant no. 099129/Z/12/Z. Fellowship assistance for BCJ (F31
AA020728) is acknowledged. We would like to thank Konstandinos Vasiliou
for his assistance.
Author details
1Department of Pharmaceutical Sciences, Molecular Toxicology and
Environmental Health Sciences Program, University of Colorado Anschutz
Medical Center, Aurora, CO 80045, USA. 2Mouse Genome Informatics, The
Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609, USA. 3HUGO
Gene Nomenclature Committee (HGNC), European Bioinformatics Institute,
EMBL-EBI, Wellcome Trust Genome Campus, Cambridge CB10 1SD, UK.
4Department of Clinical Pharmacy, University of Colorado Anschutz Medical
Center, Aurora, CO 80045, USA. 5Department of Pediatrics and Cell Biology,
University of Pittsburgh School of Medicine, Children's Hospital of UPMC,
Pittsburgh, PA 15212, USA. 6Department of Environmental Health and Center
for Environmental Genetics, University of Cincinnati Medical Center,
Cincinnati, OH 45267-0056, USA.
Received: 3 September 2013 Accepted: 15 October 2013
Published: 30 October 2013
References
1. Wright HT: Introns and higher-order structure in the evolution of serpins.
J Mol Evol 1993, 36:136–143.
2. Potempa J, Korzus E, Travis J: The serpin superfamily of proteinase
inhibitors: structure, function, and regulation. J Biol Chem 1994,
269:15957–15960.
3. Law RH, Zhang Q, McGowan S, Buckle AM, Silverman GA, Wong W, Rosado CJ,
Langendorf CG, Pike RN, Bird PI, Whisstock JC: An overview of the serpin
superfamily. Genome Biol 2006, 7:216.
4. Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PG, Irving JA,
Lomas DA, Luke CJ, Moyer RW, Pemberton PA, Remold-O'Donnell E, Salvesen GS,
Travis J, Whisstock JC: The serpins are an expanding superfamily of structurally
similar but functionally diverse proteins: evolution, mechanism of inhibition,
novel functions, and a revised nomenclature. J Biol Chem 2001,
276:33293–33296.
5. Schechter I, Berger A: On the size of the active site in proteases: I. Papain.
Biochem Biophys Res Commun 1967, 27:157–162.
6. Huber R, Carrell RW: Implications of the three-dimensional structure of
alpha 1-antitrypsin for structure and function of serpins. Biochemistry-US
1989, 28:8951–8966.
7. Rein CM, Desai UR, Church FC: Serpin-glycosaminoglycan interactions.
Methods Enzymol 2011, 501:105–137.
8. Yamasaki M, Sendall TJ, Pearce MC, Whisstock JC, Huntington JA:
Molecular basis of alpha1-antitrypsin deficiency revealed by the
structure of a domain-swapped trimer. EMBO Rep 2011, 12:1011–1017.
9. Huntington JA: Serpin structure, function and dysfunction. J Thromb
Haemost 2011, 9(1):26–34.
10. Krem MM, Di Cera E: Conserved ser residues, the shutter region, and
speciation in serpin evolution. J Biol Chem 2003, 278:37810–37814.
11. Billingsley GD, Walter MA, Hammond GL, Cox DW: Physical mapping of
four serpin genes: alpha 1-antitrypsin, alpha 1-antichymotrypsin,
corticosteroid-binding globulin, and protein C inhibitor, within a 280-kb
region on chromosome I4q32.1. Am J Hum Genet 1993, 52:343–353.
12. Rollini P, Fournier RE: A 370-kb cosmid contig of the serpin gene cluster
on human chromosome 14q32.1: molecular linkage of the genesencoding alpha 1-antichymotrypsin, protein C inhibitor, kallistatin,
alpha 1-antitrypsin, and corticosteroid-binding globulin. Genomics 1997,
46:409–415.
13. Long M, de Souza SJ, Gilbert W: Evolution of the intron-exon structure of
eukaryotic genes. Curr Opin Genet Dev 1995, 5:774–778.
14. Logsdon JM Jr, Stoltzfus A, Doolittle WF: Molecular evolution: recent cases
of spliceosomal intron gain? Curr Biol 1998, 8:R560–R563.
15. Clarke EP, Cates GA, Ball EH, Sanwal BD: A collagen-binding protein in the
endoplasmic reticulum of myoblasts exhibits relationship with serine
protease inhibitors. J Biol Chem 1991, 266:17230–17235.
16. Irving JA, Pike RN, Lesk AM, Whisstock JC: Phylogeny of the serpin
superfamily: implications of patterns of amino acid conservation for
structure and function. Genome Res 2000, 10:1845–1864.
17. Clemmensen SN, Jacobsen LC, Rorvig S, Askaa B, Christenson K, Iversen M,
Jorgensen MH, Larsen MT, van Deurs B, Ostergaard O, Heegaard NH,
Cowland JB, Borregaard N: Alpha-1-antitrypsin is produced by human
neutrophil granulocytes and their precursors and liberated during
granule exocytosis. Eur J Haematol 2011, 86:517–530.
18. Marques PI, Ferreira Z, Martins M, Figueiredo J, Silva DI, Castro P,
Morales-Hojas R, Simoes-Correia J, Seixas S: SERPINA2 is a novel gene
with a divergent function from SERPINA1. PLoS One 2013, 8:e66889.
19. Seixas S, Suriano G, Carvalho F, Seruca R, Rocha J, Di Rienzo A: Sequence
diversity at the proximal 14q32.1 SERPIN subcluster: evidence for natural
selection favoring the pseudogenization of SERPINA2. Mol Biol Evol 2007,
24:587–598.
20. Chao J, Schmaier A, Chen LM, Yang Z, Chao L: Kallistatin, a novel human
tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in
health and disease. J Lab Clin Med 1996, 127:612–620.
21. Paterson MA, Horvath AJ, Pike RN, Coughlin PB: Molecular
characterization of centerin, a germinal centre cell serpin.
Biochem J 2007, 405:489–494.
22. Heiker JT, Kloting N, Kovacs P, Kuettner EB, Strater N, Schultz S, Kern M,
Stumvoll M, Bluher M, Beck-Sickinger AG: Vaspin inhibits kallikrein 7 by
serpin mechanism. Cell Mol Life Sci 2013, 70:2569–2583.
23. Teshigawara S, Wada J, Hida K, Nakatsuka A, Eguchi J, Murakami K, Kanzaki M,
Inoue K, Terami T, Katayama A, Iseda I, Matsushita Y, Miyatake N, McDonald JF,
Hotta K, Makino H: Serum vaspin concentrations are closely related to
insulin resistance, and rs77060950 at SERPINA12 genetically defines
distinct group with higher serum levels in Japanese population.
J Clin Endocrinol Metab 2012, 97:E1202–E1207.
24. Hilgers KF, Norwood VF, Gomez RA: Angiotensin's role in renal development.
Semin Nephrol 1997, 17:492–501.
25. Vidalino L, Doria A, Quarta S, Zen M, Gatta A, Pontisso P: SERPINB3,
apoptosis and autoimmunity. Autoimmun Rev 2009, 9:108–112.
26. Tsujimoto M, Tsuruoka N, Ishida N, Kurihara T, Iwasa F, Yamashiro K, Rogi T,
Kodama S, Katsuragi N, Adachi M, Katayama T, Nakao M, Yamaichi K,
Hashino J, Haruyama M, Miura K, Nakanishi T, Nakazato H, Teramura M,
Mizoguchi H, Yamaguchi N: Purification, cDNA cloning, and characterization
of a new serpin with megakaryocyte maturation activity. J Biol Chem 1997,
272:15373–15380.
27. Miyata T, Inagi R, Nangaku M, Imasawa T, Sato M, Izuhara Y, Suzuki D,
Yoshino A, Onogi H, Kimura M, Sugiyama S, Kurokawa K: Overexpression
of the serpin megsin induces progressive mesangial cell proliferation
and expansion. J Clin Invest 2002, 109:585–593.
28. Sun J, Bird CH, Sutton V, McDonald L, Coughlin PB, De Jong TA, Trapani JA,
Bird PI: A cytosolic granzyme B inhibitor related to the viral apoptotic
regulator cytokine response modifier A is present in cytotoxic
lymphocytes. J Biol Chem 1996, 271:27802–27809.
29. Sivaprasad U, Askew DJ, Ericksen MB, Gibson AM, Stier MT, Brandt EB, Bass SA,
Daines MO, Chakir J, Stringer KF, Wert SE, Whitsett JA, Le Cras TD,
Wills-Karp M, Silverman GA, Khurana Hershey GK: A nonredundant role for
mouse serpinb3a in the induction of mucus production in asthma.
J Allergy Clin Immunol 2011, 127:254–261. 261 e251-256.
30. Gatto M, Iaccarino L, Ghirardello A, Bassi N, Pontisso P, Punzi L, Shoenfeld Y,
Doria A: Serpins, immunity and autoimmunity: old molecules, new
functions. Clin Rev Allergy Immunol 2013, 45(2):267–280.
31. Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S, Rafidi K, Seftor E,
Sager R: Maspin, a serpin with tumor-suppressing activity in human
mammary epithelial cells. Science 1994, 263:526–529.
32. Shiiba M, Nomura H, Shinozuka K, Saito K, Kouzu Y, Kasamatsu A, Sakamoto Y,
Murano A, Ono K, Ogawara K, Uzawa K, Tanzawa H: Down-regulated
Heit et al. Human Genomics 2013, 7:22 Page 13 of 14
http://www.humgenomics.com/content/7/1/22expression of SERPIN genes located on chromosome 18q21 in oral
squamous cell carcinomas. Oncol Rep 2010, 24:241–249.
33. Baldzizhar R, Fedorchuk C, Jha M, Rathinam C, Henegariu O, Czyzyk J:
Anti-serpin antibody-mediated regulation of proteases in autoimmune
diabetes. J Biol Chem 2013, 288:1612–1619.
34. Schick C, Pemberton PA, Shi GP, Kamachi Y, Cataltepe S, Bartuski AJ,
Gornstein ER, Bromme D, Chapman HA, Silverman GA: Cross-class
inhibition of the cysteine proteinases cathepsins K, L, and S by the
serpin squamous cell carcinoma antigen 1: a kinetic analysis.
Biochemistry-US 1998, 37:5258–5266.
35. Schick C, Kamachi Y, Bartuski AJ, Cataltepe S, Schechter NM, Pemberton PA,
Silverman GA: Squamous cell carcinoma antigen 2 is a novel serpin that
inhibits the chymotrypsin-like proteinases cathepsin G and mast cell
chymase. J Biol Chem 1997, 272:1849–1855.
36. Scott FL, Hirst CE, Sun J, Bird CH, Bottomley SP, Bird PI: The intracellular
serpin proteinase inhibitor 6 is expressed in monocytes and
granulocytes and is a potent inhibitor of the azurophilic granule
protease, cathepsin G. Blood 1999, 93:2089–2097.
37. Xia Y, Zhang Y, Shi W, Liu S, Chen Y, Liang X, Ye Z: Overexpression of
megsin induces mesangial cell proliferation and excretion of type IV
collagen in vitro. Cell Immunol 2011, 271:413–417.
38. Askew DJ, Cataltepe S, Kumar V, Edwards C, Pace SM, Howarth RN, Pak SC,
Askew YS, Bromme D, Luke CJ, Whisstock JC, Silverman GA: SERPINB11 Is a
new noninhibitory intracellular serpin: common single nucleotide
polymorphisms in the scaffold impair conformational change. J Biol
Chem 2007, 282:24948–24960.
39. Askew YS, Pak SC, Luke CJ, Askew DJ, Cataltepe S, Mills DR, Kato H,
Lehoczky J, Dewar K, Birren B, Silverman GA: SERPINB12 is a novel member
of the human ov-serpin family that is widely expressed and inhibits
trypsin-like serine proteinases. J Biol Chem 2001, 276:49320–49330.
40. Huntington JA: Shape-shifting serpins–advantages of a mobile
mechanism. Trends Biochem Sci 2006, 31:427–435.
41. Vicente CP, He L, Pavao MS, Tollefsen DM: Antithrombotic activity of dermatan
sulfate in heparin cofactor II-deficient mice. Blood 2004, 104:3965–3970.
42. Rau JC, Deans C, Hoffman MR, Thomas DB, Malcom GT, Zieske AW, Strong
JP, Koch GG, Church FC: Heparin cofactor II in atherosclerotic lesions from
the pathobiological determinants of atherosclerosis in youth (PDAY)
study. Exp Mol Pathol 2009, 87:178–183.
43. Lino MM, Atanasoski S, Kvajo M, Fayard B, Moreno E, Brenner HR, Suter U,
Monard D: Mice lacking protease nexin-1 show delayed structural
and functional recovery after sciatic nerve crush. J Neurosci 2007,
27:3677–3685.
44. Beinrohr L, Harmat V, Dobo J, Lorincz Z, Gal P, Zavodszky P: C1 inhibitor
serpin domain structure reveals the likely mechanism of heparin
potentiation and conformational disease. J Biol Chem 2007,
282:21100–21109.
45. Widmer C, Gebauer JM, Brunstein E, Rosenbaum S, Zaucke F, Drogemuller C,
Leeb T, Baumann U: Molecular basis for the action of the collagen-specific
chaperone Hsp47/SERPINH1 and its structure-specific client recognition.
Proc Natl Acad Sci U S A 2012, 109:13243–13247.
46. Nagai N, Hosokawa M, Itohara S, Adachi E, Matsushita T, Hosokawa N,
Nagata K: Embryonic lethality of molecular chaperone hsp47 knockout
mice is associated with defects in collagen biosynthesis. J Cell Biol 2000,
150:1499–1506.
47. Christiansen HE, Schwarze U, Pyott SM, Al Swaid A, Al Balwi M, Alrasheed S,
Pepin MG, Weis MA, Eyre DR, Byers PH: Homozygosity for a missense
mutation in SERPINH1, which encodes the collagen chaperone protein
HSP47, results in severe recessive osteogenesis imperfecta. Am J Hum
Genet 2010, 86:389–398.
48. Osterwalder T, Cinelli P, Baici A, Pennella A, Krueger SR, Schrimpf SP, Meins M,
Sonderegger P: The axonally secreted serine proteinase inhibitor,
neuroserpin, inhibits plasminogen activators and plasmin but not
thrombin. J Biol Chem 1998, 273:2312–2321.
49. Ozaki K, Nagata M, Suzuki M, Fujiwara T, Miyoshi Y, Ishikawa O, Ohigashi H,
Imaoka S, Takahashi E, Nakamura Y: Isolation and characterization of a
novel human pancreas-specific gene, pancpin, that is down-regulated in
pancreatic cancer cells. Genes Chromosomes Cancer 1998, 22:179–185.
50. Carrell RW, Lomas DA: Conformational disease. Lancet 1997, 350:134–138.
51. Saunders DN, Tindall EA, Shearer RF, Roberson J, Decker A, Wilson JA, Hayes
VM: A novel SERPINA1 mutation causing serum alpha(1)-antitrypsin
deficiency. PLoS One 2012, 7:e51762.52. Liu Y, Bledsoe G, Hagiwara M, Shen B, Chao L, Chao J: Depletion of
endogenous kallistatin exacerbates renal and cardiovascular oxidative
stress, inflammation, and organ remodeling. Am J Physiol Renal Physiol
2012, 303:F1230–F1238.
53. Jeunemaitre X, Gimenez-Roqueplo AP, Celerier J, Corvol P: Angiotensinogen
variants and human hypertension. Curr Hypertens Rep 1999, 1:31–41.
54. Van de Water N, Tan T, Ashton F, O'Grady A, Day T, Browett P, Ockelford P,
Harper P: Mutations within the protein Z-dependent protease inhibitor
gene are associated with venous thromboembolic disease: a new form
of thrombophilia. Br J Haematol 2004, 127:190–194.
55. Corral J, Gonzalez-Conejero R, Soria JM, Gonzalez-Porras JR, Perez-Ceballos E,
Lecumberri R, Roldan V, Souto JC, Minano A, Hernandez-Espinosa D, Alberca
I, Fontcuberta J, Vicente V: A nonsense polymorphism in the protein
Z-dependent protease inhibitor increases the risk for venous thrombosis.
Blood 2006, 108:177–183.
56. Gooptu B, Hazes B, Chang WS, Dafforn TR, Carrell RW, Read RJ, Lomas DA:
Inactive conformation of the serpin alpha(1)-antichymotrypsin indicates
two-stage insertion of the reactive loop: implications for inhibitory function
and conformational disease. Proc Natl Acad Sci U S A 2000, 97:67–72.
57. Torpy DJ, Bachmann AW, Gartside M, Grice JE, Harris JM, Clifton P, Easteal S,
Jackson RV, Whitworth JA: Association between chronic fatigue syndrome
and the corticosteroid-binding globulin gene ALA SER224 polymorphism.
Endocr Res 2004, 30:417–429.
58. Homan EP, Rauch F, Grafe I, Lietman C, Doll JA, Dawson B, Bertin T,
Napierala D, Morello R, Gibbs R, White L, Miki R, Cohn DH, Crawford S,
Travers R, Glorieux FH, Lee B: Mutations in SERPINF1 cause osteogenesis
imperfecta type VI. J Bone Miner Res 2011, 26:2798–2803.
59. Han MH, Hwang SI, Roy DB, Lundgren DH, Price JV, Ousman SS, Fernald GH,
Gerlitz B, Robinson WH, Baranzini SE, Grinnell BW, Raine CS, Sobel RA, Han DK,
Steinman L: Proteomic analysis of active multiple sclerosis lesions reveals
therapeutic targets. Nature 2008, 451:1076–1081.
60. Cao D, Zhang Q, Wu LS, Salaria SN, Winter JW, Hruban RH, Goggins MS,
Abbruzzese JL, Maitra A, Ho L: Prognostic significance of maspin in
pancreatic ductal adenocarcinoma: tissue microarray analysis of 223
surgically resected cases. Mod Pathol 2007, 20:570–578.
61. Vecchi M, Confalonieri S, Nuciforo P, Vigano MA, Capra M, Bianchi M, Nicosia D,
Bianchi F, Galimberti V, Viale G, Palermo G, Riccardi A, Campanini R, Daidone MG,
Pierotti MA, Pece S, Di Fiore PP: Breast cancer metastases are molecularly
distinct from their primary tumors. Oncogene 2008, 27:2148–2158.
62. Jing Y, Kovacs K, Kurisetty V, Jiang Z, Tsinoremas N, Merchan JR: Role of
plasminogen activator inhibitor-1 in urokinase's paradoxical in vivo tumor
suppressing or promoting effects. Mol Cancer Res 2012, 10:1271–1281.
63. Klein RM, Bernstein D, Higgins SP, Higgins CE, Higgins PJ: SERPINE1
expression discriminates site-specific metastasis in human melanoma.
Exp Dermatol 2012, 21:551–554.
64. Rajaraman P, Brenner AV, Butler MA, Wang SS, Pfeiffer RM, Ruder AM, Linet MS,
Yeager M, Wang Z, Orr N, Fine HA, Kwon D, Thomas G, Rothman N, Inskip PD,
Chanock SJ: Common variation in genes related to innate immunity and
risk of adult glioma. Cancer Epidemiol Biomarkers Prev 2009,
18:1651–1658.
65. Jia HL, Ye QH, Qin LX, Budhu A, Forgues M, Chen Y, Liu YK, Sun HC, Wang L,
Lu HZ, Shen F, Tang ZY, Wang XW: Gene expression profiling reveals potential
biomarkers of human hepatocellular carcinoma. Clin Cancer Res 2007,
13:1133–1139.
66. Paterson MA, Hosking PS, Coughlin PB: Expression of the serpin centerin
defines a germinal center phenotype in B-cell lymphomas. Am J Clin
Pathol 2008, 130:117–126.
67. Byrne SM, Aucher A, Alyahya S, Elder M, Olson ST, Davis DM, Ashton-
Rickardt PG: Cathepsin B controls the persistence of memory CD8+
T lymphocytes. J Immunol 2012, 189:1133–1143.
68. Safdar H, Cheung KL, Salvatori D, Versteeg HH, Laghmani el H, Wagenaar
GT, Reitsma PH, van Vlijmen BJ: Acute and severe coagulopathy in adult
mice following silencing of hepatic antithrombin and protein C
production. Blood 2013, 121:4413–4416.
69. Yiannikouris F, Karounos M, Charnigo R, English VL, Rateri DL, Daugherty A,
Cassis LA: Adipocyte-specific deficiency of angiotensinogen decreases
plasma angiotensinogen concentration and systolic blood pressure in
mice. Am J Physiol Regul Integr Comp Physiol 2012, 302:R244–R251.
70. Baumann M, Pham CT, Benarafa C: SerpinB1 is critical for neutrophil
survival through cell-autonomous inhibition of cathepsin G. Blood 2013,
121:3900–3907. S3901-3906.
Heit et al. Human Genomics 2013, 7:22 Page 14 of 14
http://www.humgenomics.com/content/7/1/2271. Zaimidou S, van Baal S, Smith TD, Mitropoulos K, Ljujic M, Radojkovic D,
Cotton RG, Patrinos GP: A1ATVar: a relational database of human
SERPINA1 gene variants leading to alpha1-antitrypsin deficiency and
application of the VariVis software. Hum Mutat 2009, 30:308–313.
72. Lane DA, Olds RJ, Thein SL: Antithrombin III: summary of first database
update. Nucleic Acids Res 1994, 22:3556–3559.
73. Kalmar L, Hegedus T, Farkas H, Nagy M, Tordai A: HAEdb: a novel
interactive, locus-specific mutation database for the C1 inhibitor gene.
Hum Mutat 2005, 25:1–5.
74. Sabina J, Tobias W: Augmentation therapy with alpha1-antitrypsin:
novel perspectives. Cardiovasc Hematol Disord Drug Targets 2013, 13:90–98.
75. Bornhorst JA, Greene DN, Ashwood ER, Grenache DG: α1-Antitrypsin
phenotypes and associated serum protein concentrations in a large
clinical population. Chest 2013, 143:1000–1008.
76. Brenner AV, Neta G, Sturgis EM, Pfeiffer RM, Hutchinson A, Yeager M, Xu L,
Zhou C, Wheeler W, Tucker MA, Chanock SJ, Sigurdson AJ: Common single
nucleotide polymorphisms in genes related to immune function and risk
of papillary thyroid cancer. PLoS One 2013, 8:e57243.
77. Almawi WY, Al-Shaikh FS, Melemedjian OK, Almawi AW: Protein Z,
an anticoagulant protein with expanding role in reproductive biology.
Reproduction 2013, 146:R73–R80.
78. Maruyama K, Morishita E, Karato M, Kadono T, Sekiya A, Goto Y, Sato T,
Nomoto H, Omi W, Tsuzura S, Imai H, Asakura H, Ohtake S, Nakao S:
Antithrombin deficiency in three Japanese families: one novel and two
reported point mutations in the antithrombin gene. Thromb Res 2013,
132:e118–e123.
79. Hepner M, Karlaftis V: Antithrombin. Methods Mol Biol 2013, 992:355–364.
80. Bork K, Davis-Lorton M: Overview of hereditary angioedema caused by
C1-inhibitor deficiency: assessment and clinical management. Eur Ann
Allergy Clin Immunol 2013, 45:7–16.
doi:10.1186/1479-7364-7-22
Cite this article as: Heit et al.: Update of the human and mouse SERPIN
gene superfamily. Human Genomics 2013 7:22.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
